Mouse Anti-BTN3A1 Recombinant Antibody (clone 103.2)

Customer Review

There are currently no Customer reviews or questions for PABL-415. Click the button above to contact us or submit your feedback about this product.

Anna Rodriguez
05.Oct,23

Reliable for BTN3A1 Detection

The Anti-BTN3A1 Recombinant Antibody (clone 103-2) has delivered excellent results in our flow cytometry and immunoassays. The specificity and sensitivity for BTN3A1 are top-notch, providing clear and accurate detection. This antibody has greatly improved our detection studies and made our experiments more reliable.

James Moore
21.Jun,22

High Specificity and Clarity

We incorporated this antibody into our Western blot and immunoprecipitation assays, and it has been a great addition. The specificity and sensitivity for BTN3A1 are outstanding, consistently detecting the target protein with high clarity. The reliable performance has made it an essential tool in our research.

Rachel Scott
30.May,21

Consistent and Reproducible

This antibody has proven to be incredibly consistent in various assays, including flow cytometry and immunofluorescence. The high-quality, reproducible results and strong affinity for BTN3A1 have significantly benefited our experiments, making it a staple in our lab. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-BTN3A1 recombinant antibody clone 103.2 suitable for use in Western blotting?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 103.2 (PABL-415) is suitable for use in Western blotting applications. It provides specific binding to BTN3A1, allowing for reliable detection of the target protein in Western blot assays.

2. What is the recommended dilution for using the anti-BTN3A1 recombinant antibody clone 103.2 in immunofluorescence?

   A: The recommended dilution for using the anti-BTN3A1 recombinant antibody clone 103.2 (PABL-415) in immunofluorescence is typically 1:100 to 1:500. It is advisable to optimize the dilution based on the specific experimental conditions and sample types.

3. Can the anti-BTN3A1 recombinant antibody clone 103.2 be used in flow cytometry analysis?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 103.2 (PABL-415) can be used in flow cytometry analysis. It is specifically designed to bind to BTN3A1, making it suitable for detecting BTN3A1-expressing cells in flow cytometry.

4. Is the anti-BTN3A1 recombinant antibody clone 103.2 effective in ELISA applications?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 103.2 (PABL-415) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of BTN3A1.

5. What are the storage recommendations for the anti-BTN3A1 recombinant antibody clone 103.2?

   A: The recommended storage condition for the anti-BTN3A1 recombinant antibody clone 103.2 (PABL-415) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Girard, Pauline, et al. "Potent bidirectional cross-talk between plasmacytoid dendritic cells and γδT cells through BTN3A, type I/II IFNs and immune checkpoints." Frontiers in Immunology 11 (2020): 861. https://doi.org/10.3389/fimmu.2020.00861
   This study investigates the potent bidirectional cross-talk between plasmacytoid dendritic cells (pDCs) and γδ T cells through BTN3A, type I/II interferons, and immune checkpoints. By co-culturing purified human pDCs and γδ T cells in the presence of various stimulants such as TLR-L, PAg, and zoledronate (Zol), the researchers aimed to mimic both infectious and tumor settings. The study found that TLR7/9L- or Zol-stimulated pDCs drive robust γδ T cell activation, Th1 cytokine secretion, and cytotoxic activity. Conversely, PAg-activated γδ T cells induce phenotypic changes and functional activities in pDCs. The study highlights the crucial interplay between these immune players, suggesting that exploiting this interaction could offer novel immunotherapeutic strategies for cancers, infections, and autoimmune diseases.
   Creative Biolabs contributed to this research by providing the anti-BTN3A blocking antibody (Cat# PABL-415). This antibody was pivotal in experiments aimed at blocking BTN3A, a molecule critical in the pDC-γδ T cell cross-talk. The use of this antibody allowed the researchers to delineate the role of BTN3A in the activation and modulation of immune responses between pDCs and γδ T cells, thereby supporting the study's exploration of new therapeutic approaches targeting these interactions.
2. Farrington, Lila A., et al. "Opsonized antigen activates Vδ2+ T cells via CD16/FCγRIIIa in individuals with chronic malaria exposure." PLoS Pathogens 16.10 (2020): e1008997. https://doi.org/10.1371/journal.ppat.1008997
   This study investigates the activation and function of Vδ2+ T cells in individuals with chronic malaria exposure. It focuses on how opsonized antigens activate these T cells via the CD16/FCγRIIIa receptor. The researchers demonstrated that in individuals with repeated malaria exposure, Vδ2 T cells show reduced TCR responsiveness but increased expression of CD16. This shift allows Vδ2 T cells to respond to opsonized P. falciparum-infected red blood cells through CD16, independent of TCR engagement. The study highlights a novel activation pathway for Vδ2 T cells that might enhance the immune response against malaria in chronically exposed individuals.
   Creative Biolabs provided critical reagents for this research, specifically the Butyrophilin 3A1 (BTN3A1) blocking antibody (Cat# PABL-415). This antibody was essential for experiments demonstrating that Vδ2 T cell activation via CD16 is independent of TCR engagement. By using this antibody, the researchers were able to confirm that BTN3A1 blockade did not inhibit the activation of Vδ2 T cells by opsonized antigens, thereby underscoring the significance of CD16-mediated activation pathways. The contribution of Creative Biolabs' products was crucial in elucidating these alternative activation mechanisms of Vδ2 T cells.
3. de Weerdt, Iris, et al. "A bispecific single-domain antibody boosts autologous Vγ9Vδ2-T cell responses toward CD1d in chronic lymphocytic leukemia." Clinical Cancer Research 27.6 (2021): 1744-1755. https://doi.org/10.1158/1078-0432.CCR-20-4576
   This study focuses on enhancing the efficacy and reducing the toxicity of autologous T cell-based therapies for chronic lymphocytic leukemia (CLL) by utilizing a bispecific single-domain antibody that targets CD1d to activate Vγ9Vδ2-T cells. The researchers evaluated CD1d expression in 78 untreated CLL patients and generated a CD1d-specific Vγ9Vδ2-T cell engager using single-domain antibodies (VHH). They demonstrated that CD1d is expressed in the majority of CLL patients, particularly those with advanced disease, and that the bispecific engager effectively activates Vγ9Vδ2-T cells, inducing robust cytotoxic responses against CLL cells. The study highlights the potential of this approach to improve the therapeutic outcomes for CLL patients by leveraging the intrinsic immunotherapeutic properties of Vγ9Vδ2-T cells.
   Creative Biolabs contributed to this research by providing the anti-BTN3A1 monoclonal antibody (Cat# PABL-415). This antibody was crucial for the experiments that involved blocking BTN3A1 to investigate the remaining phosphoantigen recognition by Vγ9Vδ2-T cells in the presence of the bispecific engager. The use of this antibody allowed the researchers to confirm the additional activation pathway of Vγ9Vδ2-T cells, thus supporting the study's goal of developing more effective and targeted immunotherapies for CLL.
4. Girard, Pauline, et al. "Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes." Clinical & Translational Immunology 10.11 (2021): e1329. https://doi.org/10.1002/cti2.1329
   This study investigates the dysfunctional BTN3A and its interaction with deregulated immune checkpoints and type I/II interferons in the context of melanoma. The research focuses on the roles of plasmacytoid dendritic cells (pDCs) and gamma-delta (γδ) T cells, examining their phenotypic and functional interactions in both the blood and tumor microenvironment of melanoma patients. The study highlights severe alterations in the bidirectional cross-talk between pDCs and γδ T cells in melanoma, noting that while healthy pDCs can drive potent activation of γδ T cells, those from melanoma patients exhibit impaired functionality.
   Creative Biolabs provided critical reagents for this study, specifically anti-BTN3A agonist antibody (clone 20.1, Cat# PABL-414) and anti-BTN3A blocking antibody (clone 103.2, Cat# PABL-415). These antibodies were used to assess the functionality of BTN3A on γδ T cells and pDCs within PBMCs and tumor infiltrates. The use of these antibodies was essential in revealing the potential functional impairment of BTN3A in melanoma patients, thereby providing insights into the therapeutic targeting of BTN3A to improve immune responses in cancer therapy​.
5. Li, Yang, et al. "The dual roles of human γδ T cells: anti-tumor or tumor-promoting." Frontiers in immunology 11 (2021): 619954. https://doi.org/10.3389/fimmu.2020.00861
   This research investigates the bidirectional cross-talk between plasmacytoid dendritic cells (pDCs) and γδT cells, two critical immune cell populations involved in immunosurveillance against pathogens and cancer. The study demonstrates that TLR7/9L- or zoledronate-stimulated pDCs drive potent γδT cell activation, enhancing Th1 cytokine secretion and cytotoxic activity. Conversely, phosphoantigen-activated γδT cells trigger pDC phenotypic changes and functional activities. The researchers identified that these interactions require both cell-cell contact and soluble factors, with type I/II interferons and BTN3A playing key roles in this cross-regulation. They also discovered that selective immune checkpoints could modulate this interplay.
   Creative Biolabs provided a crucial anti-BTN3A blocking antibody (clone 103.2) that enabled the researchers to investigate the role of BTN3A in the pDC-γδT cell cross-talk. The antibody helped establish that BTN3A is expressed by both pDCs and γδT cells and is central to their interaction, particularly in zoledronate-dependent pathways. This contribution was significant as it revealed BTN3A as a key molecular mediator in the bidirectional communication between these immune cells, offering potential new targets for immunotherapeutic strategies in cancer, infections, and autoimmune diseases.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# PABL-415, RRID: AB_3111655)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Clone 103.2"

See other products for "BTN3A1"

Select a product category from the dropdown menu below to view related products.